Lophos Pharmaceuticals Partners With Carmichael Engineering Ltd. for HVAC Project, Anticipates Expedited Building Occupancy

NAPANEE, Ontario, March 05, 2024 (GLOBE NEWSWIRE) -- Lophos Holdings Inc. ("Lophos" or the "Company") (CSE:MESC) is pleased to announce its subsidiary, Lophos Pharmaceuticals Corp., has selected Carmichael Engineering Ltd., a renowned HVAC engineering and construction firm headquartered in Belleville, ON, to drive the completion of its HVAC project and expedite occupancy at the site. This strategic partnership underscores Lophos's commitment to excellence and marks a significant advancement in its operational endeavors.

Carmichael Engineering's esteemed track record for excellence and proficiency in thermal system technologies closely aligns with Lophos's core values and strategic objectives.

Carmichael estimates that building occupancy can be attained within 4-8 weeks from the commencement of their services, providing a definitive pathway forward for Lophos. This achievement marks a pivotal milestone, strengthening the company's ability to diversify its offerings and reaffirming its commitment to expanding operational capacities.

Upon achieving building occupancy, Lophos plans to house their cultivation operations at the facility. Moreover, the site's existing Controlled Substance Dealer’s License, which permits the possession, sale, transportation, and delivery of various controlled substances including mescaline, psilocin, psilocybin, LSD, DMT, MDMA, and ketamine, will be fully utilized. Additionally, the license grants authorization for the production of mescaline, psilocin, and psilocybin.

"We are confident that Carmichael's capabilities will expedite the completion of the HVAC project," said Claire Stawnyczy, CEO at Lophos. "Their appointment marks a significant step forward in achieving occupancy of our building and advancing our objectives for our CSDL licensed facility."

Lophos reiterates its commitment to pioneering research and innovation in the study of peyote, while extending heartfelt appreciation for the ongoing support and patience demonstrated by our valued stakeholders throughout this transitional phase.

For more information, please visit our website at https://lophos.com and follow us on Twitter (@lophospharma) and LinkedIn for the latest updates and insights.

About Lophos

Lophos Pharmaceuticals Corp., a wholly-owned subsidiary of Lophos Holdings Inc. (CSE:MESC), stands as a prominent biosciences company specializing in the cultivation, research, and sale of peyote. Distinguished by its Controlled Substances Dealers License (CSDL), the subsidiary is authorized for the possession, sale, sending, transportation, and delivery of various controlled substances, including mescaline, psilocin, psilocybin, LSD, DMT, MDMA, and ketamine. Additionally, the license grants permission for the production of mescaline, psilocin, and psilocybin, showcasing the comprehensive scope of our operations.